A DREAM Challenge to Build Prediction Models for Short-Term Discontinuation of Docetaxel in Metastatic Castration-Resistant Prostate Cancer

PURPOSE: Docetaxel has a demonstrated survival benefit for patients with metastatic castration-resistant prostate cancer (mCRPC); however, 10% to 20% of patients discontinue docetaxel prematurely because of toxicity-induced adverse events, and the management of risk factors for toxicity remains a ch...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JCO Clin Cancer Inform
Main Authors: Seyednasrollah, Fatemeh, Koestler, Devin C., Wang, Tao, Piccolo, Stephen R., Vega, Roberto, Greiner, Russell, Fuchs, Christiane, Gofer, Eyal, Kumar, Luke, Wolfinger, Russell D., Kanigel Winner, Kimberly, Bare, Chris, Neto, Elias Chaibub, Yu, Thomas, Shen, Liji, Abdallah, Kald, Norman, Thea, Stolovitzky, Gustavo, Soule, Howard R., Sweeney, Christopher J., Ryan, Charles J., Scher, Howard I., Sartor, Oliver, Elo, Laura L., Zhou, Fang Liz, Guinney, Justin, Costello, James C.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2017
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6874023/
https://ncbi.nlm.nih.gov/pubmed/30657384
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/CCI.17.00018
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados